Skip header navigation

University of Stirling

×

Article

Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study

Citation
Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset P, Albarede JL, Vellas B & Grandjean H (2003) Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. Journals of Gerontology, Series A, 58 (4), pp. M372-M377. https://doi.org/10.1093/gerona/58.4.M372

Abstract
Background. Peripheral C4A treatment (cerebral and peripheral vasotherapeutics) and especially Ginkgo biloba extracts are prescribed for a number of symptoms, particularly memory impairment, in elderly patients. It is postulated that because of its pharmacological actions, this treatment could prevent the decline of cognitive function, but no studies have been published to date to test its efficacy in prevention of Alzheimer's disease. The potential association between use of C4A treatments, in particular EGb 761 (standardized Ginkgo biloba extracts), and dementia of the Alzheimer type was investigated. Methods. A case-control study was nested in a cohort of 1462 community-dwelling elderly women aged over 75 years. Sixty-nine women with Alzheimer-type dementia were compared with 345 paired women whose cognitive function remained normal. This study involved women whose cognitive function was evaluated at baseline by use of Pfeiffer's test and whose medication history was taken. The onset of cognitive impairment was investigated over a 7-year follow-up period. In order to study the factors associated with the onset of dementia, the data concerning women with a score of ≥8 on Pfeiffer's test at inclusion, indicating normal cognitive function, were analyzed. Results. A multivariate analysis including potential confounding factors showed that fewer women who developed Alzheimer's dementia had been prescribed C4A treatment (including EGb 761) for at least 2 years (odds ratio = 0.31, 95% confidence interval = 0.12-0.82, p =.018). Figures for EGb 761 alone were similar but did not reach statistical significance (odds ratio = 0.38, 95% confidence interval = 0.08-1.76, p =.22). Conclusion. These results suggest that C4A treatment may reduce the risk of developing Alzheimer's dementia in elderly women. The potential preventive effect of C4A treatments, including EGb 761, requires further examination. To establish a causal relationship, these findings have to be confirmed with prospective studies.

Journal
Journals of Gerontology, Series A: Volume 58, Issue 4

StatusPublished
Author(s)Andrieu, Sandrine; Gillette, Sophie; Amouyal, Karine; Nourhashemi, Fati; Reynish, Emma; Ousset, Pierre-Jean; Albarede, Jean Louis; Vellas, Bruno; Grandjean, Helene
Publication date30/04/2003
PublisherOxford University Press
ISSN1079-5006
Scroll back to the top